Secondary Bile Acids

Your liver makes bile acids to help you digest fat. When those bile acids reach your colon, gut bacteria transform them into a different set of molecules called secondary bile acids. The mix you produce, and the bacteria you carry, shape signals that reach your immune system, your metabolism, your liver, and even your blood vessels.

Standard panels do not measure these molecules. A secondary bile acid test gives you a window into a layer of gut and metabolic biology that routine bloodwork ignores, with growing evidence linking specific patterns to heart disease, colon cancer, fatty liver disease, type 2 diabetes, and inflammatory bowel disease.

What This Test Actually Measures

Secondary bile acids (SBAs) are formed when gut bacteria strip and reshape primary bile acids (the original molecules made by your liver from cholesterol). The two main secondary bile acids are deoxycholic acid (DCA) and lithocholic acid (LCA). Both are made primarily by Firmicutes bacteria such as Clostridium, Ruminococcaceae, and Lachnospiraceae using two key bacterial enzyme steps.

The test quantifies these molecules and their conjugated forms in stool or serum, depending on which panel you order. Both matrices reflect the same underlying biology but capture different snapshots: stool shows what is reaching and being made in the colon, while serum reflects what is circulating systemically after liver and gut handling.

Because secondary bile acids are produced by your microbiome, the test indirectly reflects gut bacterial composition, especially the species that perform two critical steps called bile salt deconjugation and 7 alpha dehydroxylation. A low secondary bile acid signature often points to disrupted gut bacteria (a state called dysbiosis).

This Is a Research-Stage Marker

Secondary bile acids do not yet have standardized clinical cutpoints. There is no guideline-set number that defines normal or abnormal for the general population. What exists is a fast-growing body of research showing that distinct patterns in healthy people, in people with metabolic risk, and in people with liver, gut, and heart conditions look measurably different.

Treat this test as exploratory. A single result tells you where you sit relative to research-reported ranges, but a tracked trend over time tells you far more than any one number.

Heart Disease Risk

Secondary bile acids appear to influence cardiovascular biology, but the picture is not a simple higher-equals-worse story. The direction of effect depends on which bile acids you measure and the population you are looking at.

In a cohort of 1,234 adults newly diagnosed with type 2 diabetes, those with the highest levels of unconjugated secondary bile acids, especially deoxycholic acid, had a higher risk of developing cardiovascular disease. In people with chronic heart failure (n=162), the ratio of secondary to primary bile acids was elevated, and a higher ratio tracked with worse survival in unadjusted analysis. In acute coronary syndrome (n=309), both primary and secondary bile acids contributed meaningfully to the risk of major cardiovascular events.

A separate study of 1,730 patients with coronary artery disease found higher unconjugated bile acid concentrations linked to lower cardiovascular and all-cause mortality. This is not a contradiction: it reflects that bile acids are phenotype indicators rather than simple good-or-bad numbers, and the direction of risk depends on which species are elevated, which are deficient, and the underlying metabolic state. The most useful read on your own data is comparing your full pattern (primary, secondary, conjugated, unconjugated) over time, not chasing a single value.

Colorectal Cancer Risk

The link between bile acids and colon cancer is one of the older and stronger associations in this field. A high-fat diet increases the bile acid load reaching your colon, and elevated secondary bile acids in that environment can promote cancer-related signaling pathways.

A prospective study of 1,138 adults found that pre-diagnostic levels of certain conjugated primary and secondary bile acids were associated with higher colon cancer risk. In another prospective analysis of 1,093 participants, higher serum bile acids and lower short-chain fatty acids were strongly associated with increased colorectal cancer risk in women, with no significant association in men. A 2025 meta-analysis concluded that higher fecal bile acid concentrations may be associated with higher colorectal cancer risk and incidence.

Tumor-tissue analysis in 228 colorectal cancer cases showed that DCA, LCA, and ursodeoxycholic acid distributions varied by tumor location, age group, and sex, and were linked to patient prognosis. The signal is real, but it is not yet a standalone screening tool.

Liver Disease, NAFLD, and Liver Cancer

Bile acids are produced by the liver, so it makes sense that liver disease distorts their patterns. What is more useful is that the patterns help distinguish stages and types of liver damage.

In 550 adults with biopsy-proven non-alcoholic fatty liver disease (NAFLD), higher secondary bile acids helped identify mild liver fibrosis (early scarring). When combined with clinical markers like waist circumference, blood pressure, and ALT (alanine aminotransferase, a liver enzyme), the model outperformed standard fibrosis scores. In 68 children with NAFLD, fecal secondary bile acids were reduced compared with healthy children, suggesting that gut bacteria were failing to convert primary to secondary bile acids.

For liver cancer, a nested case-control analysis across 12 cohorts (1,744 participants) found that higher pre-diagnostic bile acid levels were positively associated with liver cancer risk. In 200 Singapore Chinese adults, lower ratios of secondary to primary bile acids were inversely associated with hepatocellular carcinoma risk. In 744 people with HBV-related liver disease, hepatocellular carcinoma was characterized by higher secondary bile acids and lower primary bile acids, with levels linked to tumor size and stage.

Inflammatory Bowel Disease

People with inflammatory bowel disease (IBD) consistently show a distinct bile acid signature: more primary bile acids, fewer secondary ones. This shift reflects both the loss of bacteria that produce secondary bile acids and the ongoing intestinal inflammation.

In 79 adults with active ulcerative colitis, fecal bile acid composition was disrupted in proportion to disease severity. In ulcerative colitis pouch patients, secondary bile acids DCA and LCA were markedly deficient compared with controls. A separate metagenomic study of human gut microbiomes found that people with IBD have lower abundance of bile salt biotransformation genes, which translates to lower secondary bile acid production and higher primary bile acid retention.

Type 2 Diabetes and Metabolic Health

Bile acid patterns shift before type 2 diabetes is diagnosed, suggesting a role in glucose and lipid regulation. In a Chinese cohort of 54,807 normoglycemic adults followed prospectively, serum bile acid profile changes were detectable before diabetes onset. A study of 1,575 adults found that lower serum levels of hyocholic acid species (a class of bile acids related to secondary bile acid pathways) were associated with obesity and diabetes, and predicted the development of metabolic disorders 5 to 10 years later.

Across studies of 492 to 1,234 adults, prediabetes and type 2 diabetes (but not obesity alone) were associated with altered bile acid metabolism. The implication is that bile acid disruption is closer to a metabolic dysfunction signal than a weight signal.

Research-Reported Reference Values

There are no consensus clinical cutpoints for secondary bile acids. The values below come from healthy adult cohorts measured by liquid chromatography-mass spectrometry, a standard lab technique for these molecules. They are illustrative orientation, not targets. Your lab will likely report different numbers, and ranges differ significantly between serum and stool.

Compare your results within the same lab over time, in the same matrix (stool or serum), for the most meaningful trend. Switching between labs or sample types makes direct comparison unreliable.

When Results Can Be Misleading

Several factors can distort a single bile acid reading without reflecting your true baseline biology.

• High biological variability: in a study of 136 adults using both serum and fecal samples, technical reproducibility was excellent (correlations above 0.83 for most bile acids), but six-month within-person reproducibility was generally low. A single sample is a poor reflection of your longer-term levels.
• Acute illness: in 70 patients with acute respiratory distress syndrome, primary bile acids rose about 50% over five days while secondary bile acids stayed depressed. In sepsis and other critical illnesses, plasma bile acids can rise up to 11-fold. Avoid testing within several weeks of a serious infection or hospitalization.
• Recent antibiotic use: because secondary bile acids are produced by gut bacteria, recent antibiotics can dramatically reduce the bacteria responsible for making them. A reduced reading after antibiotics may reflect the medication, not your baseline.
• Bile-acid-modifying medications: ursodeoxycholic acid (UDCA), bile acid sequestrants, and FGF19 analogues like aldafermin can substantially reshape bile acid profiles. Aldafermin suppressed total and hydrophobic bile acids across multiple liver disease trials. These drugs change the reading without indicating disease status.

Tracking Your Trend Matters More Than a Single Reading

Bile acid levels move with your microbiome, your diet, your medications, and your overall metabolic state. Because of high six-month within-person variability, a single test is best treated as a starting point, not a verdict.

Get a baseline. If you make changes (a major dietary shift, a probiotic protocol, a new medication that affects gut bacteria, weight loss, or treatment for liver or gut disease), retest in 3 to 6 months. After that, retest at least annually if you are using this marker as part of a longevity or prevention plan. Two or three readings over a year give you a far more useful picture than one reading interpreted in isolation.

What to Do If Your Pattern Looks Off

An unusual secondary bile acid pattern is a starting point for investigation, not a diagnosis. The next step depends on what your pattern looks like and your other risk factors.

• Low secondary bile acids with high primary bile acids: consider a comprehensive stool microbiome panel to evaluate whether you have lost the bacterial species (Firmicutes, Clostridium, Ruminococcaceae) responsible for secondary bile acid production. Pair with a calprotectin test if you have any gut symptoms.
• High secondary bile acids, especially deoxycholic acid: review your dietary fat intake and your cardiovascular risk profile. Pair with a lipid panel including ApoB (apolipoprotein B, a measure of harmful particle count), HbA1c (a three-month average blood sugar marker), and hs-CRP (high-sensitivity C-reactive protein, an inflammation marker).
• Disrupted pattern with elevated liver enzymes: discuss with a hepatologist or gastroenterologist. Pair with a liver panel including GGT (gamma glutamyl transferase) and consider non-invasive fibrosis assessment.
• Unusual pattern with gut symptoms: discuss with a gastroenterologist. Bile acid diarrhea is a treatable condition that is frequently misdiagnosed as irritable bowel syndrome. Specialized testing including SeHCAT or serum 7 alpha-hydroxy-4-cholesten-3-one (C4) may be warranted.

The most important thing is to act on patterns, not single values, and to use this marker as one input alongside standard metabolic, lipid, and liver testing rather than in isolation.